Affiliations
AffiliationItem in Clipboard
Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectivenessJohn T Schousboe et al. Ann Intern Med. 2011.
. 2011 Jul 5;155(1):10-20. doi: 10.7326/0003-4819-155-1-201107050-00003. AffiliationItem in Clipboard
AbstractBackground: Current guidelines recommend mammography every 1 or 2 years starting at age 40 or 50 years, regardless of individual risk for breast cancer.
Objective: To estimate the cost-effectiveness of mammography by age, breast density, history of breast biopsy, family history of breast cancer, and screening interval.
Design: Markov microsimulation model.
Data sources: Surveillance, Epidemiology, and End Results program, Breast Cancer Surveillance Consortium, and the medical literature.
Target population: U.S. women aged 40 to 49, 50 to 59, 60 to 69, and 70 to 79 years with initial mammography at age 40 years and breast density of Breast Imaging Reporting and Data System (BI-RADS) categories 1 to 4.
Time horizon: Lifetime.
Perspective: National health payer.
Intervention: Mammography annually, biennially, or every 3 to 4 years or no mammography.
Outcome measures: Costs per quality-adjusted life-year (QALY) gained and number of women screened over 10 years to prevent 1 death from breast cancer.
Results of base-case analysis: Biennial mammography cost less than $100,000 per QALY gained for women aged 40 to 79 years with BI-RADS category 3 or 4 breast density or aged 50 to 69 years with category 2 density; women aged 60 to 79 years with category 1 density and either a family history of breast cancer or a previous breast biopsy; and all women aged 40 to 79 years with both a family history of breast cancer and a previous breast biopsy, regardless of breast density. Biennial mammography cost less than $50,000 per QALY gained for women aged 40 to 49 years with category 3 or 4 breast density and either a previous breast biopsy or a family history of breast cancer. Annual mammography was not cost-effective for any group, regardless of age or breast density.
Results of sensitivity analysis: Mammography is expensive if the disutility of false-positive mammography results and the costs of detecting nonprogressive and nonlethal invasive cancer are considered.
Limitation: Results are not applicable to carriers of BRCA1 or BRCA2 mutations.
Conclusion: Mammography screening should be personalized on the basis of a woman's age, breast density, history of breast biopsy, family history of breast cancer, and beliefs about the potential benefit and harms of screening.
Primary funding source: Eli Lilly, Da Costa Family Foundation for Research in Breast Cancer Prevention of the California Pacific Medical Center, and Breast Cancer Surveillance Consortium.
Conflict of interest statementPotential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-2871 .
FiguresFigure 1. Markov model of possible state…
Figure 1. Markov model of possible state transitions
The dotted-and-dashed lines indicate transitions from the…
Figure 1. Markov model of possible state transitionsThe dotted-and-dashed lines indicate transitions from the healthy state; the dashed lines indicate transitions from the DCIS state; and the solid lines indicate transitions from the invasive breast cancer states. DCIS = ductal carcinoma in situ.
Figure 2. Incidence of invasive breast cancer…
Figure 2. Incidence of invasive breast cancer as a function of age and breast density…
Figure 2. Incidence of invasive breast cancer as a function of age and breast density in U.S. womenBI-RADS = Breast Imaging Reporting and Data System; SEER = Surveillance, Epidemiology, and End Results. * Per 10 000 women per year.
Figure 3. Cost-effective mammography screening strategies for…
Figure 3. Cost-effective mammography screening strategies for women aged 40 to 79 years, by age…
Figure 3. Cost-effective mammography screening strategies for women aged 40 to 79 years, by age and breast densityStrategies assume a willingness-to-pay threshold of $100 000 (top) or $50 000 (bottom) per QALY gained. BI-RADS = Breast Imaging Reporting and Data System; QALY = quality-adjusted life-year.
Similar articlesSprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, Kerlikowske K, Lehman CD, Tosteson AN. Sprague BL, et al. Ann Intern Med. 2015 Feb 3;162(3):157-66. doi: 10.7326/M14-0692. Ann Intern Med. 2015. PMID: 25486550 Free PMC article.
Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, Gangnon RE, Hampton JM, Chandler Y, de Koning HJ, Mandelblatt JS, Tosteson AN; Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network. Trentham-Dietz A, et al. Ann Intern Med. 2016 Nov 15;165(10):700-712. doi: 10.7326/M16-0476. Epub 2016 Aug 23. Ann Intern Med. 2016. PMID: 27548583 Free PMC article.
Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, Buist DS, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson AN, Mandelblatt JS. Stout NK, et al. J Natl Cancer Inst. 2014 May 28;106(6):dju092. doi: 10.1093/jnci/dju092. Print 2014 Jun. J Natl Cancer Inst. 2014. PMID: 24872543 Free PMC article.
Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L. Nelson HD, et al. Ann Intern Med. 2016 Feb 16;164(4):256-67. doi: 10.7326/M15-0970. Epub 2016 Jan 12. Ann Intern Med. 2016. PMID: 26756737 Review.
Feig S. Feig S. Radiol Clin North Am. 2010 Sep;48(5):879-91. doi: 10.1016/j.rcl.2010.06.002. Radiol Clin North Am. 2010. PMID: 20868891 Review.
Eklund M, Broglio K, Yau C, Connor JT, Stover Fiscalini A, Esserman LJ. Eklund M, et al. JNCI Cancer Spectr. 2019 Jan 8;2(4):pky067. doi: 10.1093/jncics/pky067. eCollection 2018 Oct. JNCI Cancer Spectr. 2019. PMID: 31360882 Free PMC article.
Tan M, Zheng B, Ramalingam P, Gur D. Tan M, et al. Acad Radiol. 2013 Dec;20(12):1542-50. doi: 10.1016/j.acra.2013.08.020. Acad Radiol. 2013. PMID: 24200481 Free PMC article.
Li Y, Carlson E, Hernández DA, Green B, Calle T, Kumaresan T, Madondo K, Martinez M, Villarreal R, Meraz L, Pagán JA. Li Y, et al. Health Equity. 2019 Jun 20;3(1):280-286. doi: 10.1089/heq.2018.0089. eCollection 2019. Health Equity. 2019. PMID: 31236527 Free PMC article.
Molloi S, Ducote JL, Ding H, Feig SA. Molloi S, et al. Med Phys. 2014 Aug;41(8):081917. doi: 10.1118/1.4890295. Med Phys. 2014. PMID: 25086548 Free PMC article.
Sak MA, Littrup PJ, Duric N, Mullooly M, Sherman ME, Gierach GL. Sak MA, et al. Breast Cancer Manag. 2015;4(4):209-221. doi: 10.2217/bmt.15.13. Epub 2015 Aug 28. Breast Cancer Manag. 2015. PMID: 28943893 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3